Photo of Steven P. Treon,  MD, PhD

Steven P. Treon, MD, PhD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-2681
Fax: (617) 632-4862


steven_treon@dfci.harvard.edu

Steven P. Treon, MD, PhD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Director, Bing Center for Waldenstrom's Macroglobulinemia, Adult Oncology, Dana-Farber Cancer Institute

DF/HCC PROGRAM AFFILIATION

Research Abstract

Our research has focused on understanding the genetic basis and pathogenesis of Waldenström’s Macroglobulinemia (WM), and the development of therapeutics for this B-cell malignancy which effects 6,000-10,000 patients a year in the United States. As part of these efforts, we recently characterized the existence of a familial form of Waldenström’s Macroglobulinemia, describing its incidence, clinical, laboratory and cytogenetic characteristics. Importantly as part of these efforts, we demonstrated differing patterns of gene losses among WM patients including BLIMP1, PAX5 and members of the unfolded protein response (UPR) including XBP1 and IRE1a. Most recently our studies have underscored that patients with WM have constitutive IgA and IgG hypogammaglobulinemia and mutations in APRIL and its signaling receptor TACI akin to those found in patients with Common Variable Immunodeficiency Syndrome (CVID), underscoring that CVID may serve as a predisposition to WM. We have also focused our studies on understanding what genetic mechanisms underscore the loss of homeostasis in WM by demonstrating the cell surface loss of CD27 and its adapter molecule SIVA which are regulated by soluble and cell surface CD70 presented by immunoregulatory cells including T- and mast cells. Our studies have also gained important insight into the pathogenesis of Waldenström’s Macroglobulinemia by demonstrating a role for the excess mast cells found in the bone marrows of patients with WM. We recently demonstrated that mast cells serve as potent inducers of growth and enhancers of tumor cell survival through a host of mediators including CD40 ligand, A proliferation inducing ligand (APRIL), B-lymphocyte stimulator (B-LYS) protein, platelet derived growth factor (PDGFa) and vascular endothelial growth factor (VEGF), while also showing that WM tumor cells through soluble CD27 induce expression of several of these ligands. These revelations have helped in the development of novel therapeutic strategies targeting mast cells and mast-cell-tumor cell interactions in WM. In addition to the above studies, we have also sought to advance the therapy for WM by conducting clinical trials utilizing monoclonal antibodies, as single agents and in combination with nucleoside analogs, cytotoxic agents, and immunomodulating agents, as well as phosphodiesteraase and proteosome inhibitors. As part of these efforts we have defined in our lab the mechanisms of action and resistance for these agents, and in particular the role of Fc gamma receptor polymorphisms in predicting clinical responses to the CD20 directed monoclonal antibody rituximab. The above work has established several novel agents for the therapy of WM, while ongoing trials are being conducted to enhance the efficacy toxicity.

Publications

Powered by Harvard Catalyst
  • Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2015. PubMed
  • Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Survival outcomes of secondary cancers in patients with waldenstr旦m macroglobulinemia: An analysis of the SEER database. Am J Hematol 2015. PubMed
  • Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH. Ibrutinib in previously treated Waldenstr旦m's macroglobulinemia. N Engl J Med 2015; 372:1430-40. PubMed
  • Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. British Journal of Haematology 2015; 169:81-9. PubMed
  • Castillo JJ, Olszewski AJ, Hunter ZR, Kanan S, Meid K, Treon SP. Incidence of secondary malignancies among patients with Waldenstr旦m macroglobulinemia: An analysis of the SEER database. Cancer 2015. PubMed
  • Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang X, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ. Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenstr旦m's Macroglobulinemia. Clin Cancer Res 2015. PubMed
  • Cao Y, Hunter ZR, Liu X, Xu L, Yang G, Chen J, Tsakmaklis N, Kanan S, Castillo JJ, Treon SP. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr旦m macroglobulinaemia cells. British Journal of Haematology 2015; 168:701-7. PubMed
  • Leblebjian H, Noonan K, Paba-Prada C, Treon SP, Castillo JJ, Ghobrial IM. Cyclophosphamide, bortezomib and dexamethasone (CyBorD) combination in Waldenstrom Macroglobulinemia. Am J Hematol 2015. PubMed
  • Banwait R, Aljawai Y, Cappuccio J, McDiarmid S, Morgan EA, Leblebjian H, Roccaro AM, Laubach J, Castillo JJ, Paba-Prada C, Treon S, Redd R, Weller E, Ghobrial IM. Extramedullary Waldenstr旦m macroglobulinemia. Am J Hematol 2015; 90:100-4. PubMed
  • Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, Tsakmaklis N, Hatjiharissi E, Kanan S, Davids MS, Castillo JJ, Treon SP. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4(Wild-type) and CXCR4(WHIM) mutated Waldenstrom macroglobulinaemia cells. British Journal of Haematology 2015. PubMed
  • Castillo JJ, Ghobrial IM, Treon SP. Biology, prognosis, and therapy of Waldenstr旦m Macroglobulinemia. Cancer Treat Res 2015; 165:177-95. PubMed
  • Treon SP, Hunter ZR, Castillo JJ, Merlini G. Waldenstr旦m Macroglobulinemia. Hematol Oncol Clin North Am 2014; 28:945-970. PubMed
  • Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenstr旦m macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 2014; 124:1404-11. PubMed
  • Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP. Survival trends in Waldenstr旦m macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood 2014; 123:3999-4000. PubMed
  • Treon SP, Tripsas CK, Meid K, Kanan S, Sheehy P, Chuma S, Xu L, Cao Y, Yang G, Liu X, Patterson CJ, Warren D, Hunter ZR, Turnbull B, Ghobrial IM, Castillo JJ. Carfilzomib, rituximab and dexamethasone (CaRD) is active and offers a neuropathy-sparing approach for proteasome-inhibitor based therapy in Waldenstrom's macroglobulinemia. Blood 2014. PubMed
  • Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, Gray NS. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol 2014. PubMed
  • Zhou Y, Liu X, Xu L, Hunter ZR, Cao Y, Yang G, Carrasco R, Treon SP. Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenstr旦m macroglobulinaemia. British Journal of Haematology 2014. PubMed
  • Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 2014. PubMed
  • Fulciniti M, Amodio N, Bandi RL, Munshi M, Yang G, Xu L, Hunter Z, Tassone P, Anderson KC, Treon SP, Munshi NC. MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood 2014; 123:2673-81. PubMed
  • Zhao JJ, Lin J, Zhu D, Wang X, Brooks D, Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, Tao J, Tai YT, Treon S, Pinkus G, Kuo WP, Hideshima T, Bouxsein M, Munshi N, Anderson K, Carrasco R. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/硫-catenin/BCL9 pathway. Cancer Res 2014; 74:1801-13. PubMed
  • Hunter ZR, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Manning RJ, Tripsas C, Patterson CJ, Sheehy P, Treon SP. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2014; 123:1637-46. PubMed
  • Ghobrial IM, Witzig TE, Gertz M, LaPlant B, Hayman S, Camoriano J, Lacy M, Bergsagel PL, Chuma S, DeAngelo D, Treon SP. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol 2014; 89:237-42. PubMed
  • Sahin I, Leblebjian H, Treon SP, Ghobrial IM. Waldenstr旦m macroglobulinemia: from biology to treatment. Expert Rev Hematol 2014; 7:157-68. PubMed
  • Treon SP. Proteasome inhibitors in Waldenstr旦m macroglobulinemia. Blood 2013; 122:3243-4. PubMed
  • Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, Anderson KC, Hunter ZR, Treon SP. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr旦m macroglobulinemia. Blood 2013; 122:1222-32. PubMed
  • Treon SP, Tripsas C, Ciccarelli BT, Manning RJ, Patterson CJ, Sheehy P, Hunter ZR. Patients With Waldenstr旦m Macroglobulinemia Commonly Present With Iron Deficiency and Those With Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration. Clin Lymphoma Myeloma Leuk 2013. PubMed
  • Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, Varettoni M, Varettoni M, Brown JR, Tai YT, Anderson KC, Munshi NC, Patterson CJ, Manning RJ, Tripsas CK, Lindeman NI, Treon SP. MYD88 L265P in Waldenstr旦m macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013; 121:2051-8. PubMed
  • Sacco A, Zhang Y, Maiso P, Manier S, Rossi G, Treon SP, Ghobrial IM, Roccaro AM. microRNA Aberrations in Waldenstr旦m Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013. PubMed
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R. Multiple myeloma, version 1.2013. J Natl Compr Canc Netw 2013; 11:11-7. PubMed
  • Treon SP, Tripsas C, Hanzis C, Ioakimidis L, Patterson CJ, Manning RJ, Sheehy P, Turnbull B, Hunter ZR. Familial disease predisposition impacts treatment outcome in patients with waldenstr旦m macroglobulinemia. Clin Lymphoma Myeloma Leuk 2012; 12:433-7. PubMed
  • Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP. Response assessment in Waldenstr旦m macroglobulinaemia: update from the VIth International Workshop. British Journal of Haematology 2012. PubMed
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA. Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013. J Natl Compr Canc Netw 2012; 10:1211-1219. PubMed
  • Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR. MYD88 L265P somatic mutation in Waldenstr旦m's macroglobulinemia. N Engl J Med 2012; 367:826-33. PubMed
  • Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, Hu Y, Lin J, Zhao JJ, Cagnetta A, Cea M, Sellitto MA, Zhong MY, Wang Q, Acharya C, Carrasco DR, Buggy JJ, Elias L, Treon SP, Matsui W, Richardson P, Munshi NC, Anderson KC. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120:1877-87. PubMed
  • Grass S, Preuss KD, Wikowicz A, Terpos E, Ziepert M, Nikolaus D, Yang Y, Fadle N, Regitz E, Dimopoulos MA, Treon SP, Hunter ZR, Pfreundschuh M. Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. Blood 2011; 117:2918-23. PubMed
  • Treon SP, Hanzis C, Tripsas C, Ioakimidis L, Patterson CJ, Manning RJ, Sheehy P. Bendamustine Therapy in Patients With Relapsed or Refractory Waldenstr旦m's Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11:133-5. PubMed
  • Sun JY, Xu L, Tseng H, Ciccarelli B, Fulciniti M, Hunter ZR, Maghsoudi K, Hatjiharissi E, Zhou Y, Yang G, Zhu B, Liu X, Gong P, Ioakimidis L, Sheehy P, Patterson CJ, Munshi NC, O'Connor OA, Treon SP. Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenstr旦m's Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11:152-6. PubMed
  • Hanzis C, Ojha RP, Hunter Z, Manning R, Lewicki M, Brodsky P, Ioakimidis L, Tripsas C, Patterson CJ, Sheehy P, Treon SP. Associated Malignancies in Patients with Waldenstr旦m's Macroglobulinemia and Their Kin. Clin Lymphoma Myeloma Leuk 2011; 11:88-92. PubMed
  • Ciccarelli BT, Patterson CJ, Hunter ZR, Hanzis C, Ioakimidis L, Manning R, Yang G, Xu L, Zhou Y, Sun J, Liu X, Tseng H, Cao Y, Sheehy P, Rodig SJ, Treon SP. Hepcidin Is Produced by Lymphoplasmacytic Cells and Is Associated With Anemia in Waldenstr旦m's Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11:160-3. PubMed
  • Treon SP, Merlini G, Morra E, Patterson CJ, Stone MJ. Report From the Sixth International Workshop on Waldenstr旦m's Macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011; 11:68-73. PubMed
  • Treon SP. Fc粒 receptor predictive genomic testing and the treatment of indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010; 10:321-2. PubMed
  • Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr旦m Macroglobulinemia. Am J Hematol 2010; 85:670-4. PubMed
  • Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010; 115:5385-92. PubMed
  • Dimopoulos MA, Chen C, Kastritis E, Gavriatopoulou M, Treon SP. Bortezomib as a treatment option in patients with Waldenstr旦m macroglobulinemia. Clin Lymphoma Myeloma Leuk 2010; 10:110-7. PubMed
  • Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28:1408-14. PubMed
  • Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28:1422-8. PubMed
  • Hunter ZR, Manning RJ, Hanzis C, Ciccarelli BT, Ioakimidis L, Patterson CJ, Lewicki MC, Tseng H, Gong P, Liu X, Zhou Y, Yang G, Sun J, Xu L, Sheehy P, Morra M, Treon SP. IgA and IgG hypogammaglobulinemia in Waldenstr旦m's macroglobulinemia. Haematologica 2010; 95:470-5. PubMed
  • Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc 2010; 85:197-9; author reply 201-4. PubMed
  • Treon SP. How I treat Waldenstr旦m macroglobulinemia. Blood 2009; 114:2375-85. PubMed
  • Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM. Primary therapy of Waldenstr旦m macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009; 27:3830-5. PubMed
  • Morel P,Duhamel A,Gobbi P,Dimopoulos MA,Dhodapkar MV,McCoy J,Crowley J,Ocio EM,Garcia-Sanz R,Treon SP,Leblond V,Kyle RA,Barlogie B,Merlini G. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113:4163-70. PubMed
  • Treon SP,Branagan AR,Ioakimidis L,Soumerai JD,Patterson CJ,Turnbull B,Wasi P,Emmanouilides C,Frankel SR,Lister A,Morel P,Matous J,Gregory SA,Kimby E. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 113:3673-8. PubMed
  • Leleu X,Hunter ZR,Xu L,Roccaro AM,Moreau AS,Santos DD,Hatjiharissi E,Bakthavachalam V,Adamia S,Ho AW,Soumerai J,Patterson CJ,Manning RJ,Hamilton S,Verselis S,Fox E,Carrasco R,Ghobrial IM,Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. British Journal of Haematology 2009; 145:59-63. PubMed
  • Leleu X,Tamburini J,Roccaro A,Morel P,Soumerai J,Levy V,Wemeau M,Balkaran S,Poulain S,Hunter ZR,Ghobrial IM,Treon SP,Leblond V. Balancing risk versus benefit in the treatment of Waldenstrom's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma 2009; 9:71-3. PubMed
  • Ciccarelli BT,Yang G,Hatjiharissi E,Ioakimidis L,Patterson CJ,Manning RJ,Xu L,Liu X,Tseng H,Gong P,Sun J,Zhou Y,Treon SP. Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:56-8. PubMed
  • Treon SP,Patterson CJ,Kimby E,Stone MJ. Advances in the biology and treatment of Waldenstrom's macroglobulinemia: a report from the 5th International Workshop on Waldenstrom's Macroglobulinemia, Stockholm, Sweden. Clin Lymphoma Myeloma 2009; 9:10-5. PubMed
  • Menke MN,Feke GT,McMeel JW,Treon SP. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:100-3. PubMed
  • Ioakimidis L,Patterson CJ,Hunter ZR,Soumerai JD,Manning RJ,Turnbull B,Sheehy P,Treon SP. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009; 9:62-6. PubMed
  • Leleu X,Xu L,Jia X,Sacco A,Farag M,Hunter ZR,Moreau AS,Ngo HT,Hatjiharissi E,Ho AW,Santos DD,Adamia S,O'Connor K,Ciccarelli B,Soumerai J,Manning RJ,Patterson CJ,Roccaro AM,Ghobrial IM,Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood 2008; 113:626-34. PubMed
  • Leleu X,Soumerai J,Roccaro A,Hatjiharissi E,Hunter ZR,Manning R,Ciccarelli BT,Sacco A,Ioakimidis L,Adamia S,Moreau AS,Patterson CJ,Ghobrial IM,Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2008; 27:250-5. PubMed
  • Dimopoulos MA,Gertz MA,Kastritis E,Garcia-Sanz R,Kimby EK,Leblond V,Fermand JP,Merlini G,Morel P,Morra E,Ocio EM,Owen R,Ghobrial IM,Seymour J,Kyle RA,Treon SP. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol 2008; 27:120-6. PubMed
  • Treon SP,Soumerai JD,Branagan AR,Hunter ZR,Patterson CJ,Ioakimidis L,Chu L,Musto P,Baron AD,Nunnink JC,Kash JJ,Terjanian TO,Hyman PM,Nawfel EL,Sharon DJ,Munshi NC,Anderson KC. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009; 15:355-60. PubMed
  • Adamia S,Reichert AA,Kuppusamy H,Kriangkum J,Ghosh A,Hodges JJ,Pilarski PM,Treon SP,Mant MJ,Reiman T,Belch AR,Pilarski LM. Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia. Blood 2008; 112:5111-21. PubMed
  • Ho AW, Hatjiharissi E, Ciccarelli BT, Branagan AR, Hunter ZR, Leleu X, Tournilhac O, Xu L, O'Connor K, Manning RJ, Santos DD, Chemaly M, Patterson CJ, Soumerai JD, Munshi NC, McEarchern JA, Law CL, Grewal IS, Treon SP. CD27-CD70 interactions in the pathogenesis of Waldenstrom's Macroglobulinemia. Blood 2008; 112:4683-9. PubMed
  • Treon SP,Soumerai JD,Branagan AR,Hunter ZR,Patterson CJ,Ioakimidis L,Briccetti FM,Pasmantier M,Zimbler H,Cooper RB,Moore M,Hill J 2nd,Rauch A,Garbo L,Chu L,Chua C,Nantel SH,Lovett DR,Boedeker H,Sonneborn H,Howard J,Musto P,Ciccarelli BT,Hatjiharissi E,Anderson KC. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008; 112:4452-7. PubMed
  • Moreau AS,Jia X,Patterson CJ,Roccaro AM,Xu L,Sacco A,O'Connor K,Soumerai J,Ngo HT,Hatjiharissi E,Hunter ZR,Ciccarelli B,Manning R,Ghobrial IM,Leleu X,Treon SP. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. British Journal of Haematology 2008; 142:775-85. PubMed
  • Moreau AS, Sebti Y, Duhamel A, Roccaro AM, Coiteux V, Gastinne T, Friec GL, Burwick N, Amiot L, Ho AW, Poulain S, Hennache B, Hunter ZR, Dessaint JP, Ghobrial IM, Treon SP, Facon T, Zorn E, Leleu X. Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. Eur J Haematol 2008; 80:503-9. PubMed
  • Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melham MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM. Targeting NF-{kappa}B in Waldenstrom macroglobulinemia. Blood 2008; 111:5068-77. PubMed
  • Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R, Nelson M, Leduc R, Robu D, Dupire S, Hatjiharissi E, Burwick N, Darre S, Hennache B, Treon SP, Facon T, Gertz MA, Ghobrial IM. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008. PubMed
  • Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenstrom's macroglobulinemia. Clin Cancer Res 2008; 14:1849-58. PubMed
  • Treon SP, Hatjiharissi E, Merlini G. Waldenstrom's macrogloblinemia/ lymphoplasmacytic lymphoma. Cancer Treat Res 2008; 142:211-42. PubMed
  • Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, Roccaro A, O'Sullivan G, McMillin DW, Moreno D, Kiziltepe T, Carrasco R, Treon SP, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007; 110:4417-26. PubMed
  • Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP. Increased natural killer cell expression of CD16, and augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIA-158 V/V and V/F polymorphism. Blood 2007; 110:2561-4. PubMed
  • Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MA, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, Adamia S, Kriangkum J, Kutok JL, Tai YT, Zhang J, Pilarski LM, Anderson KC, Munshi N, Treon SP. Establishment of BCWM.1 cell line for Waldenstrom's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol 2007; 35:1366-75. PubMed
  • Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial I. Novel agents in the treatment of Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2007; 7 Suppl 5:S199-206. PubMed
  • Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, Cook D, Songer J, Hill J, Kaden BR, Sharon D, Steiss R, Leleu X, Branagan AR, Badros A. Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248. Clin Cancer Res 2007; 13:3320-5. PubMed
  • Moreau AS, Jia X, Ngo HT, Leleu X, O'sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallanian S, Hatjiharissi E, Raab MS, Xu L, Treon SP, Hideshima T, Anderson KC, Ghobrial IM. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007; 109:4964-72. PubMed
  • Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, George D, Lu G, Ghobrial J, Alsayed Y, Zeismer S, Cabanela M, Nehme A, Jia X, Moreau AS, Treon SP, Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM. Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res 2007; 67:3777-84. PubMed
  • Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006; 12:7174-9. PubMed
  • Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, Goyal RK, Anderson KC, Munshi NC. Specific killing of multiple myeloma cells by (-)- epigallocatechin-3-gallate extracted from green tea: biological activity and therapeutic implications. Blood 2006; 108:2804-10. PubMed
  • Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S, Catley L, Hunter Z, Branagan AR, Boyce JA, Munshi N, Anderson KC, Treon SP. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 2006; 17:1275-82. PubMed
  • Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006; 42:1564-73. PubMed
  • Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 2006; 6:478-83. PubMed
  • Tassone P, Neri P, Kutok JL, Tournilhac O, Santos DD, Hatjiharissi E, Munshi V, Venuta S, Anderson KC, Treon SP, Munshi NC. A SCID-hu in vivo model of human Waldenstr旦m macroglobulinemia. Blood 2005; 106:1341-5. PubMed
  • Adamia S, Treon SP, Reiman T, Tournilhac O, McQuarrie C, Mant MJ, Belch AR, Pilarski LM. Potential impact of a single nucleotide polymorphism in the hyaluronan synthase 1 gene in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 5:253-6. PubMed
  • Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 5:273-7. PubMed
  • Hunter ZR, Branagan AR, Manning R, Patterson CJ, Santos DD, Tournilhac O, Dorfman DM, Treon SP. CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005; 5:246-9. PubMed
  • Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstr's macroglobulinemia. J Clin Oncol 2005; 23:474-81. PubMed
  • Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005; 128:192-203. PubMed
  • Treon SP, Emmanouilides C, Kimby E, Kelliher A, Preffer F, Branagan AR, Anderson KC, Frankel SR,. Extended rituximab therapy in Waldenstr's macroglobulinemia. Ann Oncol 2004; 16:132-8. PubMed
  • Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 2004; 125:343-52. PubMed
  • Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 2004; 64:2846-52. PubMed
  • Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenstr's macroglobulinemia. Hematology Am Soc Hematol Educ Program 2004. PubMed
  • Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res 2003; 63:6689-96. PubMed
  • Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol 2003; 121:592-6. PubMed
  • Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T, Munshi NC, Treon SP, Anderson KC. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 2002; 101:2762-9. PubMed
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002; 99:14374-9. PubMed
  • Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002; 21:5673-83. PubMed
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002; 99:4525-30. PubMed
  • Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood 2002; 99:4079-86. PubMed
  • Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood 2002; 99:2162-71. PubMed
  • Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ, Ellman L, Harmon D, Grossbard ML, Anderson KC. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002; 25:72-81. PubMed
  • Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Lentzsch S, Davies FE, Chauhan D, Schlossman RL, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI, Anderson KC. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001; 15:1950-61. PubMed
  • Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 2001; 98:795-804. PubMed
  • Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP. Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias. Expert Opin Investig Drugs 2002; 10:1521-30. PubMed
  • Treon SP, Agus TB, Link B, Rodrigues G, Molina A, Lacy MQ, Fisher DC, Emmanouilides C, Richards AI, Clark B, Lucas MS, Schlossman R, Schenkein D, Lin B, Kimby E, Anderson KC, Byrd JC. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 2001; 24:272-9. PubMed
  • Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001; 24:263-71. PubMed
  • Tai YT, Teoh G, Lin B, Davies FE, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Podar K, Anderson KC. Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage. J Immunol 2000; 165:6347-55. PubMed
  • Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2001; 27:79-85. PubMed
  • Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96:2943-50. PubMed
  • Treon SP, Maimonis P, Bua D, Young G, Raje N, Mollick J, Chauhan D, Tai YT, Hideshima T, Shima Y, Hilgers J, von Mensdorff-Pouilly S, Belch AR, Pilarski LM, Anderson KC. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood 2000; 96:3147-53. PubMed
  • Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, Shima Y, Tai YT, Rosen S, Avraham S, Kharbanda S, Anderson KC. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000; 275:27845-50. PubMed
  • Raje N, Kica G, Chauhan D, Zhang Y, Teoh G, Treon SP, Hideshima T, Deng JH, Gao SJ, Alsina M, Wally J, Davies FE, Tai YT, Pinkus GS, Pinkus JL, Skinner M, Comenzo RL, Anderson KC. Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. Amyloid 2000; 7:126-32. PubMed
  • Hideshima T, Chauhan D, Teoh G, Raje N, Treon SP, Tai YT, Shima Y, Anderson KC. Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6. Clin Cancer Res 2000; 6:1180-9. PubMed
  • Tai YT, Teoh G, Shima Y, Chauhan D, Treon SP, Raje N, Hideshima T, Davies FE, Anderson KC. Isolation and characterization of human multiple myeloma cell enriched populations. J Immunol Methods 2000; 235:11-9. PubMed
  • Teoh G, Tai YT, Urashima M, Shirahama S, Matsuzaki M, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Anderson KC. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood 2000; 95:1039-46. PubMed
  • Treon SP, Shima Y, Grossbard ML, Preffer FI, Belch AR, Pilarski LM, Anderson KC. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann Oncol 2000; 11 Suppl 1:107-11. PubMed
  • Raje N, Gong J, Chauhan D, Teoh G, Avigan D, Wu Z, Chen D, Treon SP, Webb IJ, Kufe DW, Anderson KC. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood 1999; 93:1487-95. PubMed
  • Urashima M, DeCaprio JA, Chauhan D, Teoh G, Ogata A, Treon SP, Hoshi Y, Anderson KC. p16INK4A promotes differentiation and inhibits apoptosis of JKB acute lymphoblastic leukemia cells. Blood 1997; 90:4106-15. PubMed
  • Urashima M, Teoh G, Ogata A, Chauhan D, Treon SP, Hoshi Y, DeCaprio JA, Anderson KC. Role of CDK4 and p16INK4A in interleukin-6-mediated growth of multiple myeloma. Leukemia 1997; 11:1957-63. PubMed
  • Chauhan D, Pandey P, Ogata A, Teoh G, Treon S, Urashima M, Kharbanda S, Anderson KC. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism. Oncogene 1997; 15:837-43. PubMed
  • Urashima M, Chen BP, Chen S, Pinkus GS, Bronson RT, Dedera DA, Hoshi Y, Teoh G, Ogata A, Treon SP, Chauhan D, Anderson KC. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997; 90:754-65. PubMed
  • Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, Schlossman RL, Anderson KC. Interleukin-6 overcomes p21WAF1 upregulation and G1 growth arrest induced by dexamethasone and interferon-gamma in multiple myeloma cells. Blood 1997; 90:279-89. PubMed
  • Ogata A, Chauhan D, Urashima M, Teoh G, Treon SP, Anderson KC. Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. Clin Cancer Res 1998; 3:1017-22. PubMed
Hide